Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other neoplasm 1

Conditions

Breast Neoplasms 1786Neoplasms 1512Carcinoma, Non-Small-Cell Lung 1046Prostatic Neoplasms 958Colorectal Neoplasms 884Lung Neoplasms 804Pancreatic Neoplasms 577Carcinoma, Hepatocellular 543Leukemia, Myeloid, Acute 539Stomach Neoplasms 516Ovarian Neoplasms 511Neoplasm Metastasis 495Multiple Myeloma 492Recurrence 416Melanoma 387Squamous Cell Carcinoma of Head and Neck 372Brain Neoplasms 362Uterine Cervical Neoplasms 361Head and Neck Neoplasms 355Esophageal Neoplasms 318Precursor Cell Lymphoblastic Leukemia-Lymphoma 312Lymphoma 307Endometrial Neoplasms 305Triple Negative Breast Neoplasms 298Glioblastoma 298Rectal Neoplasms 285Urinary Bladder Neoplasms 268Sarcoma 265Hematologic Neoplasms 265Colonic Neoplasms 256

Interventions

thymoglobulin 1fludarabine phosphate 1fludarabine 1Whole-Body Irradiation 1Stem Cell Transplantation 1Sirolimus 1Mycophenolic Acid 1Hematopoietic Stem Cell Transplantation 1Cyclophosphamide 1Antilymphocyte Serum 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Non-Malignant Neoplasm × Clear all
NCT04083183 2025-12-18

Total Body Irradiation and Astatine-211-Labeled BC8-B10 Monoclonal Antibody for the Treatment of Nonmalignant Diseases

Fred Hutchinson Cancer Center

Phase 1/2 Recruiting
40 enrolled
Other neoplasm

Non-Malignant Neoplasm

Data powered by HemOnc (CC BY 4.0) Colophon âš¡